In 2023, among the countries analyzed, Switzerland led in genito-urinary system and sex hormones sales per capita at $36, followed closely by the Czech Republic at $35.2, and Iceland at $32. Notable year-on-year increases were observed in New Zealand (+7.07%), Ireland (+4.78%), and Australia (+4.06%). However, some countries like Austria (-1.95%) and Luxembourg (-1.1%) showed a decline in sales. Looking at the past five years, compounded annual growth rates indicate a stable yet modest increase, with most countries experiencing yearly growth rates around 1-2%.
Future trends to watch for in the global genito-urinary system and sex hormones market include:
- Potential market expansion in countries with significant year-on-year growth, such as New Zealand and Ireland.
- The impact of healthcare policy changes on sales, particularly in Europe.
- The influence of emerging biotechnologies and new drug approvals on market dynamics.
Top countries in Genito Urinary System and Sex Hormones Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Switzerland | 36 | 2023 | +1.41% | +1.15% | View data |
| 2 | 2 Czech Republic | 35.2 | 2023 | +13.55% | +0.82% | View data |
| 3 | 3 Iceland | 32 | 2023 | +0.63% | +1.99% | View data |
| 4 | 4 Portugal | 29.1 | 2023 | +0.69% | +1.74% | View data |
| 5 | 5 Chile | 27.1 | 2023 | +5.45% | +1.38% | View data |
| 6 | 6 Belgium | 26.3 | 2023 | -2.59% | +1.1% | View data |
| 7 | 7 Ireland | 24 | 2023 | +1.27% | +4.78% | View data |
| 8 | 8 Norway | 23.7 | 2023 | +6.28% | +0.43% | View data |
| 9 | 9 Spain | 22.8 | 2023 | +2.24% | +1.47% | View data |
| 10 | 10 Denmark | 20.6 | 2023 | 0% | +0.2% | View data |
